Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV004791720 | SCV005413667 | likely pathogenic | not provided | 2023-12-20 | criteria provided, single submitter | clinical testing | PP3, PM1, PM2_moderate, PS3_moderate, PS4_moderate |
Prevention |
RCV004730427 | SCV005340633 | uncertain significance | FGG-related disorder | 2024-05-30 | no assertion criteria provided | clinical testing | The FGG c.1015A>C variant is predicted to result in the amino acid substitution p.Ser339Arg. This variant is also referred to p.Ser313Arg or Detroit II in the literature. This variant has been reported in the heterozygous state in individuals with hypodysfibrinogenemia (Brennan et al. 2010. PubMed ID: 20126833; Chen et al. 2022. doi: 10.3760/cma.j.cn114452-20220426-00254). It has not been reported in a large population database indicating this variant is rare. Other missense variants affecting this amino acid (p.Ser339Asn, p.Ser339Gloy, p.Ser339Ile) have been reported in individuals with dysfibrinogenemia or hypofibrinogenemia (Kotlín et al. 2014. PubMed ID: 25074738; Meyer et al. 2006. PubMed ID: 16607083; Zhu et al. 2018. PubMed ID: 29652987). Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |